Our current focus in oncology includes cancer stem cells as targets for chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and triple negative breast cancer (TNBC).  Our lead program is in CML where our lead agent, ES-3000 reduces β-catenin. Wnt/β-catenin is a critical cancer stem cell survival pathway.

Chronic myeloid leukemia (CML) is caused by...

Acute myeloid leukemia (AML) is the most common acute leukemia...

Pancreatic cancer is the fourth...